THERAPY DOSSIER · th-02100e2ad19a

FK866 (NAMPT inhibitor) and nicotinamide mononucleotide (NMN)

Drug · NAMPT inhibitor (INHIBITOR), direct interaction

Evidence & regulatory context

Mechanism: NAMPT inhibitor (INHIBITOR), direct interaction
Target: CHEMBL1744525
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL566757 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: FK866; FK-866; APO866; APO-866; Daporinad; K 22.175
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00432107 ↗PHASE2completed

Phase II APO866 in advanced melanoma

Melanoma

Enrolment: 25 · Results not recorded

NCT00431912 ↗PHASE2completed

Phase II APO866 in refractory/relapsed cutaneous T-cell lymphoma

Cutaneous T-cell Lymphoma

Enrolment: 25 · Results not recorded

NCT00435084 ↗PHASE1/PHASE2completed

Phase I/II APO866 in refractory B-cell CLL

B-cell Chronic Lymphocytic Leukemia

Enrolment: 10 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25684751 ↗2015Reported benefit

NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.

MouseTBICryogenicBALB/cMale

Model: Cortical cryoinjury model of traumatic brain injury

Both FK866 and NMN reduced neuronal loss and lesion volume at 24 h and day 14. FK866 additionally attenuated astrocyte and macrophage/microglia activation and lowered NAD, whereas NMN restored NAD without anti-inflammatory effects.

Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…